How should obstructive sleep apnea be screened and managed in individuals with Down syndrome?

Screening and Management of Obstructive Sleep Apnea in Down Syndrome

All individuals with Down syndrome should undergo polysomnography (PSG) screening for obstructive sleep apnea given the 50-100% prevalence in childhood and near-universal prevalence in adulthood, with first-line treatment being adenotonsillectomy for severe OSA, followed by CPAP/NIV for persistent or recurrent disease. 1

Screening Approach

Universal PSG Screening is Essential

• Screen all individuals with Down syndrome regardless of symptoms, as OSA prevalence reaches 50-100% in childhood and approaches 100% in adulthood 1
• Clinical screening tools have failed validation - a 2023 study showed negative predictive values of only 50% for AHI >1 and 73.7% for AHI >5, making questionnaire-based screening unreliable 2
• Exception for adults: The STOP-Bang questionnaire (≥3 points) showed 100% sensitivity and 100% negative predictive value for moderate-severe OSA in adults with DS and may be useful for initial screening 3

Timing of Screening

• Earliest screening in first year of life - OSA is most frequently identified and most severe in infancy, with an inverse relationship between age and OSA severity 4
• Priority populations for early PSG:
  • Infants requiring NICU care
  • Those with feeding difficulties/failure to thrive
  • Airway abnormalities (laryngomalacia)
  • Pulmonary hypertension
  • Aspiration history 4

What Constitutes Abnormal

• OSA defined as nocturnal CO₂ >50 mmHg for ≥2% of sleep time or >5 consecutive minutes 1
• In one cohort, 94% of children with DS who underwent PSG had abnormal studies, with 60% showing moderate-severe OSA 4

Management Algorithm

Step 1: Adenotonsillectomy for Severe OSA

• Adenotonsillectomy is the preferred first-line treatment for severe OSAS 1
• Critical caveat: Surgery is significantly less effective in DS compared to general population - 30-50% continue to have persistent or recurrent OSA post-operatively 1
• Mandatory post-operative PSG is essential given the 65% rate of residual OSA after adenotonsillectomy 5, 6

Step 2: CPAP/NIV for Persistent or Recurrent OSA

NIV has become a cornerstone treatment for OSA in Down syndrome given high surgical failure rates 1

Indications for CPAP/NIV:

• Post-adenotonsillectomy persistent OSA
• OSA with preference for nonsurgical treatment
• Hypoventilation or nocturnal hypercapnia
• Failed or recurrent OSA after surgery 1

Efficacy Data:

• CPAP reduces AHI from 41.2 to 5.3 events/hour at 8-10 weeks and 4.3 events/hour at 8 months (p<0.001) 1
• Adherence is achievable: 87% still using CPAP at 8-10 weeks, 70% at 8 months, with 74-77% showing acceptable adherence 1
• In pediatric cohorts, mean compliance of 8 hours 46 minutes per night achieved, with 82% using >4 hours/night 6

Clinical Benefits Beyond AHI:

• Improved daytime sleepiness, behavior (reduced irritability, anxiety, antisocial behavior)
• Better cognitive outcomes (verbal and nonverbal intelligence scores)
• Improved emotional regulation and reduced internalizing behaviors 1, 7

Critical Pitfalls and Solutions

Anatomical Challenges Affecting Mask Fit:

• Flat nasal bridge, nuchal folds, obesity, macroglossia complicate mask fitting
• Ear anatomy makes securing lower mask strap difficult
• Solution: Careful mask selection and fitting; consider custom interfaces; avoid over-tightening which causes skin injury and reduces compliance 1

Hospital Initiation is Key:

• Poor initial experience leads to long-term non-adherence
• Start CPAP/NIV in hospital setting with proper desensitization and family training before home use 1

Ongoing Monitoring:

• Serial PSG studies are necessary - one study showed median age at OSA diagnosis was paradoxically higher (5.9 years) after 2011 guideline publication, suggesting delayed diagnosis remains problematic 5
• Monitor for treatment failure given anatomical progression with age

Quality of Life Considerations

Untreated OSA in Down syndrome significantly impacts:

• Executive function, particularly emotional regulation
• Language development (expressive and receptive vocabulary)
• Behavioral outcomes (internalizing and externalizing behaviors)
• Social functioning
• Cognitive development 7

Treatment of OSA improves these outcomes, making aggressive screening and management essential for optimizing developmental trajectories and quality of life in this population.